Financial Performance - The company's operating revenue for Q1 2023 was ¥107,504,828.76, representing a year-on-year increase of 9.67%[5]. - Total operating revenue for Q1 2023 was ¥107,504,828.76, an increase of 9.98% compared to ¥98,027,811.38 in Q1 2022[18]. - Total operating costs decreased to ¥147,310,606.74 in Q1 2023 from ¥150,663,048.75 in Q1 2022, a reduction of 2.35%[18]. - Net profit for Q1 2023 was -¥31,354,681.56, an improvement from -¥37,033,436.97 in Q1 2022, reflecting a decrease in net loss of approximately 15.5%[19]. - Total profit for Q1 2023 was -¥40,234,419.96, compared to -¥45,243,906.72 in Q1 2022, indicating a reduction in losses[19]. Cash Flow - The net cash flow from operating activities was -¥147,248,515.51, indicating significant cash outflow[6]. - Operating cash flow for Q1 2023 was -¥147,248,515.51, slightly better than -¥157,222,315.08 in Q1 2022[20]. - The net cash flow from investing activities for Q1 2023 was -¥5,606,283.95, compared to -¥51,911,438.05 in Q1 2022, showing a significant reduction in cash outflow[21]. - The company generated ¥99,076,074.81 in cash from sales in Q1 2023, down from ¥105,143,461.21 in Q1 2022[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,406,706,803.49, down 4.78% from the end of the previous year[6]. - As of March 31, 2023, the total current assets amounted to RMB 2,114,696,359.84, a decrease of 6.45% from RMB 2,260,656,635.23 on December 31, 2022[14]. - The cash and cash equivalents decreased to RMB 618,345,584.94 from RMB 851,754,652.56, representing a decline of 27.36%[14]. - The total liabilities decreased to RMB 593,655,097.97, down 13.66% from RMB 687,479,956.03[16]. - The total equity attributable to shareholders decreased to RMB 1,788,687,399.99 from RMB 1,807,350,479.33, a decline of 1.83%[16]. - The company’s total assets decreased to RMB 2,406,706,803.49 from RMB 2,527,653,625.57, a reduction of 4.78%[15]. Shareholder Information - The company had a total of 5,549 common shareholders at the end of the reporting period[10]. - The largest shareholder, Xia Jun, held 17.91% of the shares, totaling 24,690,198 shares[10]. Research and Development - Research and development expenses totaled ¥53,749,878.60, accounting for 50.00% of operating revenue, a decrease of 3.08 percentage points[6]. - Research and development expenses for Q1 2023 were ¥44,689,485.21, a decrease of 6.9% from ¥48,010,998.55 in Q1 2022[18]. Earnings Per Share - The net profit attributable to shareholders was a loss of ¥22,660,220.88, with a diluted earnings per share of -¥0.16[5][6]. - The company reported a basic and diluted earnings per share of -¥0.16 for Q1 2023, an improvement from -¥0.20 in Q1 2022[19]. Audit Information - The company did not conduct an audit for the first quarter financial statements[4]. Inventory and Receivables - The inventory increased to RMB 557,170,481.95 from RMB 529,008,844.29, reflecting a growth of 5.32%[15]. - The accounts receivable slightly increased to RMB 412,786,738.47 from RMB 407,388,910.73, a rise of 1.00%[14]. Non-Recurring Gains - The company reported non-recurring gains of ¥1,777,752.68 after tax adjustments[8]. Borrowings - The company’s short-term borrowings significantly decreased to RMB 10,199,999.98 from RMB 85,094,154.82, a drop of 88.00%[16]. Return on Equity - The weighted average return on equity was -1.29%[6].

Financial Performance - The company reported a net loss of RMB 26,941,913.58 as of December 31, 2022, indicating that it does not meet the conditions for profit distribution[5]. - The company has not declared any statutory surplus reserves or discretionary reserves for the year 2022 due to negative retained earnings[5]. - The company's operating revenue for 2022 was approximately ¥716.95 million, representing a year-on-year increase of 9.97% compared to ¥651.94 million in 2021[22]. - Net profit attributable to shareholders for 2022 was approximately ¥64.58 million, a significant increase of 30.18% from ¥49.61 million in 2021[22]. - The basic earnings per share for 2022 was ¥0.47, a decrease of 2.08% from ¥0.48 in 2021[24]. - The weighted average return on equity decreased to 3.65% in 2022, down by 6.92 percentage points from 10.57% in 2021[24]. - The net cash flow from operating activities decreased by ¥61.73 million compared to the previous year, primarily due to delayed customer payments and increased upfront investments in medical information projects[25]. - The company's total net assets attributable to shareholders increased to approximately ¥1.81 billion by the end of 2022, a growth of 4.18% from ¥1.73 billion at the end of 2021[22]. - The company reported a net loss of approximately ¥28.29 million in the first quarter of 2022, followed by a profit of ¥63.10 million in the fourth quarter[28]. - The company reported a negative net cash flow from operating activities of -25,921.78 million, indicating significant cash flow challenges[120]. - The company has experienced significant seasonal revenue fluctuations, with most income recognized in the second half of the year, particularly in Q4[118]. Research and Development - Research and development expenses accounted for 24.71% of operating revenue in 2022, an increase of 5.47 percentage points from 19.24% in 2021[24]. - The company's R&D investment reached 177.15 million yuan, an increase of 41.24% compared to the previous year[36]. - Total R&D investment increased by 41.24% year-on-year, reaching ¥177,152,231.62, with R&D expenses accounting for 24.71% of operating revenue, an increase of 5.47 percentage points[90]. - The company has applied for 18 new invention patents and received authorization for 8 invention patents during the reporting period[37]. - The company has developed 5 new core technologies that significantly enhance medical data interconnectivity and utilization during the reporting period[82]. - The company has established a comprehensive marketing network across 15 provinces and municipalities, enhancing customer service and interaction[112]. Market Position and Strategy - The company is listed on the Shanghai Stock Exchange under the stock code 688246[19]. - The company has maintained the number one position in the electronic medical record (EMR) market in China for eight consecutive years from 2014 to 2021, according to IDC data[73]. - The company has over 1,550 hospital clients, including more than 500 top-tier hospitals, accounting for over 25% of all top-tier hospitals in China[73]. - The company aims to become a leading enterprise in the domestic medical information industry, focusing on clinical information construction and following the development path of "informationization-digitalization-intelligentization"[167]. - The company plans to enhance its competitive barriers in clinical medical data production, centralization, and application by leveraging its electronic medical record technology and innovative data generation models[169]. - The company is actively expanding its product line, including specialized electronic medical record systems and smart medical solutions, to address the needs of various types of medical institutions[170]. Governance and Compliance - The company has received a standard unqualified audit report from Da Hua Certified Public Accountants[4]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for providing guarantees[7]. - The company has not made any significant governance arrangements or special matters applicable[8]. - The company has implemented multiple quality management systems, including ISO9001 and ISO13485, ensuring high standards in data and business security[112]. - The company confirmed the remuneration assessment system for directors and senior management, which requires approval from the board and shareholders[197]. Risks and Challenges - The company has detailed potential risks in its report, which investors should be aware of[6]. - The company faces risks related to increasing accounts receivable, which may impact cash flow and operational performance[120]. - The company is at risk of losing core technical personnel, which could adversely affect its operations and technological development[115]. - The company has identified risks associated with project implementation without signed contracts, leading to potential revenue recognition issues[116]. - The company faces risks related to changes in tax incentives, which could increase tax liabilities if the conditions for tax benefits are not met[123]. Investment and Financial Management - The company has completed the investment of $5,772,470 in the Emergency Clinical Information System V2.0, with a total expected investment of $21,250,000[94]. - The company has invested $4,626,911 in the Jiahe Platform Data Center V6.0, with a total expected investment of $14,000,000, achieving significant improvements in data quality and processing efficiency[94]. - The company has completed the investment of $3,895,769 in the Haisen Clinical Decision Support System V3.0, with a total expected investment of $7,100,000, enhancing clinical decision-making through natural language processing[94]. - The company has invested $2,773,991 in the Haisen AI Teaching Assistant System V1.0, with a total expected investment of $4,450,000, aimed at improving clinical skills for specific rare diseases[95]. - The company has completed the investment of $6,913,104 in the Haisen Big Data Research and Analysis Platform V3.0, with a total expected investment of $12,000,000, facilitating retrospective clinical research[95]. Product Development and Innovation - The company plans to continue expanding its product offerings and enhancing its technological capabilities in response to market trends and policy support[24]. - The company is committed to continuous technological innovation, exploring applications of cloud computing, IoT, big data, AI, and mobile internet in the medical information field[168]. - The company is focused on improving the user experience and market competitiveness of its product lines through upgrades and iterations of existing systems[170]. - The company is leveraging AI applications to promote the capabilities and service levels of grassroots medical institutions, supporting the implementation of hierarchical medical care policies[170]. Customer Engagement and Market Expansion - The company is enhancing its brand awareness and overall strength through competitive compensation systems and equity incentives to attract high-quality talent[172]. - The company is focused on expanding its market presence and developing new technologies in the healthcare sector[194]. - The company is involved in multiple partnerships and collaborations to enhance its service offerings in the healthcare industry[194]. - The company plans to implement new strategies to enhance customer engagement, targeting a J% increase in customer retention rates[185].

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2024, representing a year-on-year increase of 15%[14]. - The company's operating revenue for the first half of the year was approximately CNY 300.48 million, representing a 2.92% increase compared to the same period last year[19]. - The total revenue for the reporting period was 604.5 million RMB, with a net profit of 122.36 million RMB, indicating a strong financial performance[52]. - The company achieved a revenue of 300.48 million yuan, representing a year-on-year growth of 2.92%[62]. - The company reported a significant performance decline, with a reduction in revenue by 20% year-over-year[115]. - The company reported a net loss of CNY 125,548,761.89 for the current period, compared to a net loss of CNY 84,417,293.52 in the previous period, indicating a worsening financial performance[186]. User Engagement and Market Expansion - User data indicates that the active user base has grown to 1.5 million, up 20% compared to the same period last year[14]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[14]. - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of 2025[116]. - User data showed a growth of 30% in active users year-over-year, reaching 1.5 million users[118]. Research and Development - Research and development expenses increased by 30% to RMB 15 million, focusing on innovative healthcare solutions and technology advancements[14]. - The company has a strong focus on R&D, integrating traditional software technology with new-generation information technology to enhance its product offerings[33]. - The company applied for 26 new invention patents and obtained 6 invention patent authorizations during the reporting period, bringing the total number of authorized invention patents to 51[39]. - The company has developed six core technologies for specialized electronic medical records, enhancing data usability and precision in medical decision-making[56]. - The company has made significant investments in R&D for smart clinical, smart management, and medical AI technologies[63]. Technology and Product Development - The company has launched a new electronic medical record system, which is anticipated to increase operational efficiency by 25%[14]. - The company has developed a new core technology, "Large Model Assisted Electronic Medical Record Automatic Generation Technology," which utilizes deep learning to generate structured medical documents, reducing manual input time for doctors[33]. - The company has developed an intelligent, automated, and comprehensive quality control platform for medical records, which aims to enhance the quality control process in hospitals and is currently in the trial operation phase[51]. - The company has completed the development of a smart hospital system, which includes a patient-side app and a doctor-side workstation app, aimed at enhancing communication and service efficiency[52]. - The company is collaborating with its subsidiary to upgrade emergency diagnosis systems, integrating imaging and ultrasound diagnostic products[66]. Financial Management and Risks - The company has recognized a tax reduction to 15% for its subsidiaries recognized as high-tech enterprises, but future changes in tax policies could adversely affect its financial performance[80]. - The company faces risks related to the medical information industry, including potential policy changes that could impact order acquisition and revenue growth stability[81]. - The company has improved its internal control management and cash flow management to strengthen its risk resistance capabilities[62]. - The company reported a negative net cash flow from operating activities of -189.85 million yuan, primarily due to delayed payments from clients and high upfront project investments[78]. Shareholder and Equity Information - The company did not propose any profit distribution or capital reserve fund transfer plans for the half-year period[100]. - The company has committed to a cash dividend policy, ensuring reasonable returns to investors, with specific arrangements for profit distribution outlined in the company's articles of association[121]. - The total number of ordinary shareholders as of the reporting period end was 5,867[146]. - The company’s total share capital was adjusted to 137,570,846 shares after the exercise of stock options and the cancellation of repurchased shares[145]. Environmental and Social Responsibility - The company has implemented green office measures to reduce carbon emissions[108]. - The company is not classified as a key pollutant unit and does not belong to heavily polluting industries[106]. - The company has established an environmental management system and obtained ISO14001:2015 certification[107]. - There were no administrative penalties related to environmental issues during the reporting period[106].

Financial Performance - The company's operating revenue for the third quarter was ¥175,272,087.55, a decrease of 28.68% compared to the same period last year[4]. - The net profit attributable to shareholders was -¥13,787,288.80, representing a decline of 133.47% year-over-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥13,248,115.02, down 132.78% from the previous year[4]. - The net profit attributable to shareholders for the year-to-date period was -¥41,259,537.59, a significant decrease of 328.81% compared to the same period last year[4]. - The company reported a net loss of CNY 72,563,428.01 for the first three quarters of 2024, compared to a loss of CNY 19,149,698.80 in the same period of 2023[21]. - The total profit (loss) for the period was -73,586,781.02 RMB, compared to -19,188,968.02 RMB in the previous period[22]. - The net profit attributable to the parent company's shareholders was -41,259,537.59 RMB, down from 18,032,060.98 RMB year-over-year[23]. - The basic and diluted earnings per share for the third quarter were both -¥0.10, reflecting a decline of 133.33% year-over-year[5]. - The basic and diluted earnings per share were both -0.30 RMB, compared to 0.13 RMB in the same period last year[23]. Research and Development - Research and development expenses totaled ¥56,676,943.62, accounting for 32.34% of operating revenue, an increase of 9.06 percentage points year-over-year[5]. - Research and development expenses for the first three quarters of 2024 amounted to CNY 116,607,510.81, compared to CNY 127,290,711.34 in 2023, indicating a decrease of 8.3%[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,659,989,627.58, a slight increase of 0.54% from the end of the previous year[5]. - Total assets as of September 30, 2024, were CNY 2,659,989,627.58, slightly up from CNY 2,645,633,863.79 at the end of 2023[17]. - Total liabilities increased to CNY 889,967,888.54 as of September 30, 2024, compared to CNY 817,330,281.60 at the end of 2023, marking an increase of 8.8%[17]. - The company's equity attributable to shareholders decreased to CNY 1,773,506,823.62 as of September 30, 2024, down from CNY 1,821,580,993.57 at the end of 2023, a decline of 2.6%[17]. Cash Flow - The company reported a cash flow from operating activities of -¥162,335,536.26 for the year-to-date period[4]. - Cash flow from operating activities generated a net outflow of -162,335,536.26 RMB, an improvement from -226,519,885.58 RMB in the previous year[24]. - Cash inflow from investment activities was 30,477,529.64 RMB, significantly lower than 110,636,068.16 RMB in the prior year[25]. - Cash flow from financing activities resulted in a net inflow of 65,093,607.61 RMB, compared to a net outflow of -54,693,186.32 RMB last year[25]. - The total cash and cash equivalents at the end of the period were 303,496,223.85 RMB, down from 382,650,059.49 RMB at the end of the previous year[25]. - Cash and cash equivalents decreased to CNY 328,568,394.05 as of September 30, 2024, down from CNY 612,478,452.28 at the end of 2023, representing a decline of 46.3%[16]. - The company received 12,878,824.78 RMB in tax refunds, an increase from 8,746,067.31 RMB in the previous year[24]. - The company reported a decrease in cash received from sales of goods and services, totaling 366,295,717.03 RMB, compared to 371,112,264.71 RMB in the same period last year[24]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,576[11]. - The largest shareholder, Xia Jun, holds 24,750,839 shares, representing 17.99% of total shares[11]. - The second largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 16,812,069 shares, representing 12.22%[11]. - The third largest shareholder, Hongyun Jiukang Data Technology (Beijing) Co., Ltd., holds 11,650,207 shares, representing 8.47%[11]. - The top 10 shareholders collectively hold significant stakes, with the largest three shareholders accounting for 38.68% of total shares[11]. - The company has a total of 4,604,868 shares held by Suzhou Saifu Puxin Medical Health Industry Investment Center, representing 3.35%[12]. - The total number of shares held by the top 10 unrestricted shareholders is 42,000,000 shares[12]. - The company has engaged in margin trading, with specific shares held through this method, including 1,765,000 shares by Beijing Haoqing Wealth Investment Management Co., Ltd.[13]. - The company has not reported any significant changes in shareholder structure due to margin trading activities[14]. Operational Status - There are no other important reminders regarding the company's operational status during the reporting period[14]. - The company did not execute any mergers or acquisitions during the reporting period[26].

Financial Performance - The company's operating revenue for Q3 2023 was CNY 245,755,766.88, representing a year-on-year increase of 20.82%[5] - The net profit attributable to shareholders for Q3 2023 was CNY 41,194,041.14, reflecting a significant increase of 50.95% compared to the same period last year[5] - The basic earnings per share for Q3 2023 was CNY 0.30, up 50.00% from CNY 0.13 in the same quarter last year[6] - The net profit attributable to shareholders for the year-to-date period reached CNY 18,032,060.98, marking a substantial increase of 1,121.77% compared to the same period last year[5] - The diluted earnings per share for the year-to-date period was CNY 0.30, reflecting a 1,200.00% increase from CNY 0.13 in the previous year[6] - Total operating revenue for the first three quarters of 2023 reached ¥537,712,968.92, an increase of 18.1% compared to ¥455,321,747.12 in the same period of 2022[21] - Net profit for the first three quarters of 2023 was ¥1,117,873.06, a significant improvement from a net loss of ¥18,939,625.90 in the same period of 2022[22] - The company reported a basic earnings per share of ¥0.13 for the first three quarters of 2023, compared to ¥0.01 in the same period of 2022[23] Research and Development - Research and development expenses totaled CNY 57,220,973.67 in Q3 2023, which is 23.28% of operating revenue, an increase of 1.01 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2023 were ¥127,290,711.34, a decrease of 6.5% from ¥135,334,064.77 in the same period of 2022[21] - The company has not disclosed any significant new product or technology developments during the reporting period[16] Cash Flow and Liquidity - The cash flow from operating activities for Q3 2023 was negative at CNY -30,823,444.92, with a year-to-date total of CNY -226,519,885.58[6] - Cash flow from operating activities for the first three quarters of 2023 was ¥371,112,264.71, an increase from ¥346,747,837.31 in the previous year[25] - The net cash flow from operating activities was -226,519,885.58, an improvement from -288,844,282.25 in the previous period[26] - The total cash outflow from operating activities was 633,077,028.10, compared to 690,529,882.61 previously[26] - The company received 100,000,000.00 in cash from investment recoveries[26] - The ending balance of cash and cash equivalents was 382,650,059.49, down from 555,579,181.95 in the previous period[27] Assets and Liabilities - The total assets at the end of Q3 2023 were CNY 2,461,794,791.87, a decrease of 2.61% from the end of the previous year[6] - Total current assets decreased from ¥2,260,656,635.23 at the end of 2022 to ¥2,070,333,698.01, a decline of approximately 8.4%[19] - Non-current assets increased from ¥266,996,990.34 at the end of 2022 to ¥391,461,093.86, an increase of about 46.6%[19] - Total liabilities decreased to ¥614,510,868.05 in 2023 from ¥687,479,956.03 in 2022, reflecting a reduction of approximately 10.6%[20] - Shareholders' equity increased to ¥1,847,283,923.82 in 2023, compared to ¥1,840,173,669.54 in 2022, indicating a slight growth[20] - The total assets and liabilities ratio was approximately 0.97 in 2023, down from 1.00 in 2022, suggesting improved financial stability[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,617[13] - The largest shareholder, Xia Jun, holds 24,750,839 shares, representing 17.88% of total shares[13] Financial Management - The company reported a financial expense of -¥2,495,914.87, an improvement from -¥8,757,501.08 in the previous year, indicating better financial management[21] - The company has invested ¥70,402,293.48 in development expenditures as of September 30, 2023, compared to ¥18,360,179.85 at the end of 2022, an increase of approximately 283.5%[19]

Financial Performance - The net profit attributable to the parent company for 2023 is CNY 32,284,480.94, while the consolidated undistributed profit is CNY -98,076,513.10[4] - The company will not distribute profits for 2023 due to existing undistributed losses and plans to cancel repurchased shares to enhance earnings per share[4] - The company's operating revenue for 2023 was ¥695,175,319.22, a decrease of 3.04% compared to ¥716,948,756.64 in 2022[21] - Net profit attributable to shareholders decreased by 50.01% to ¥32,284,480.94 from ¥64,578,165.82 in the previous year[21] - The net cash flow from operating activities improved by ¥116,115,977.11 compared to the previous year, although it remained negative at -¥143,101,783.01[24] - Basic earnings per share decreased by 51.06% to ¥0.23 from ¥0.47 in 2022[22] - Total assets increased by 4.67% to ¥2,645,633,863.79 at the end of 2023, compared to ¥2,527,653,625.57 at the end of 2022[21] - The weighted average return on equity decreased to 1.78% from 3.65% in the previous year, a decline of 1.87 percentage points[23] Research and Development - Research and development expenses accounted for 32.72% of operating revenue, an increase of 8.01 percentage points from 24.71% in 2022[23] - Research and development investment reached 227.43 million yuan, an increase of 28.38% year-on-year, with 82.50 million yuan capitalized and 144.93 million yuan expensed[33] - The company applied for 40 new invention patents and received authorization for 17 patents during the reporting period, totaling 45 authorized invention patents by the end of the period[34] - The company has developed a medical decision-making engine with a diagnostic accuracy rate exceeding 98% in clinical applications[26] - The company has successfully integrated multiple statistical and machine learning algorithms for risk prediction and analysis in healthcare[28] - The company has accumulated 8 core technologies in smart healthcare, with 34 authorized invention patents and 42 invention patents pending[73] Market Position and Recognition - The company ranked first in the electronic medical record market for the ninth consecutive year, as reported by IDC in July 2023[44] - In 2022, the company held an 8.8% market share in the medical big data sector, ranking first in China for the fourth consecutive year[45] - The company was recognized as one of the top 50 most influential enterprises in medical health information technology in 2023[45] - The company ranks first in the Chinese medical big data solution market in 2022, as reported by IDC[72] - The company has established a nationwide marketing network with over 1,600 clients, reflecting a strong brand presence and customer loyalty[107] Corporate Governance - The company has not disclosed any special arrangements for corporate governance[7] - The company strictly adheres to the regulations of the Company Law, Securities Law, and the Shanghai Stock Exchange's listing rules, ensuring a well-structured governance framework[161] - The governance structure is continuously improved to align with regulatory requirements, ensuring compliance and operational integrity[161] - The company has implemented stock incentive plans for key personnel, with notable increases in shareholdings for several executives, such as Ren Yong, who received 135.90 thousand yuan in remuneration[166] Strategic Initiatives and Future Outlook - The company is focusing on the integration of high-quality medical data management, driven by policies promoting the development of public hospitals[37] - The company is actively exploring the development of AI technologies to enhance existing products, particularly in the field of medical data utilization[34] - The company plans to invest in the development of specialized electronic medical records and clinical research products based on AI and big data technologies, aiming to improve the quality and efficiency of core business in medical institutions[157] - The company aims to become a leading enterprise in the domestic medical information industry, focusing on clinical information construction and following the development path of "informationization - digitalization - intelligentization"[154] Challenges and Risks - The management has highlighted potential risks in the future plans and development strategies, cautioning investors about uncertainties[5] - The company faces risks related to market competition and the need for continuous technological upgrades to maintain its competitive advantage[109] - The company is exposed to risks from changes in tax incentives, which could increase tax liabilities and negatively impact financial performance[115] - The company faced risks related to weak receivables collection, particularly from medical institutions, which could adversely affect cash flow and operational performance[112] Employee and Talent Development - The number of R&D personnel increased to 705, representing 34.39% of the total workforce, compared to 34.96% in the previous period[99] - The company has established a comprehensive professional training system to enhance employee skills and management capabilities[192] - The company is committed to establishing a talent introduction and incentive mechanism to improve employee loyalty and attract high-quality external experts[158] Technology and Innovation - The integration of new technologies such as big data, AI, cloud computing, and IoT is revolutionizing the efficiency and effectiveness of the healthcare industry[68] - The company has developed a smart medical data platform that processes and analyzes large-scale heterogeneous medical data, enhancing patient services and clinical decision support[73] - The technology for automatic generation of medical records supports over 1,100 specialty diagnoses and includes more than 400 treatment plans and 1,700 specialty medical record templates[76] Financial Management - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 6.061 million RMB[175] - The total remuneration for core technical personnel at the end of the reporting period was 3.9966 million RMB[176] - The company has a clear salary policy based on fairness, competitiveness, and performance, ensuring timely payment of wages[190]

| 嘉和美康于2021年12月14日在上交所科创板上市，发行价格为39.50元/股，发行数量为3446.94万股，保荐机构 | | --- | | (主承销商)为华泰联合证券有限责任公司，保荐代表人为孔祥熙、王琛。目前该股处于破发状态。 | | 主要会计数据 | 2024年 | 2023年 | 本期比上 年同期增 | 2022年 | | --- | --- | --- | --- | --- | | | | | 減(%) | | | 营业收入 | 591, 944, 324. 71 | 695, 175, 319. 22 | -14. 85 | 716. 948. 756. 64 | | 扣除与主营业务无关 的业务收入和不具备 | 591, 944, 324. 71 | 695, 175, 319, 22 | -14. 85 | 716. 948. 756. 64 | | 商业实质的收入后的 | | | | | | 营业收入 | | | | | | 归属于上市公司股东 | -256, 117, 402. 41 | 32, 284, 480. 94 | -893. 31 | 64. 578. 165. 82 | ...

中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 嘉和美康(北京)科技股份有限公司 2024年度合并及母公司财务报表 审计报告书 目 录 一、审计报告 二、审计报告附送 1. 合并及母公司资产负债表 2. 合并及母公司利润表 3. 合并及母公司现金流量表 4. 合并股东权益变动表 5. 母公司股东权益变动表 6. 财务报表附注 三、审计报告附件 1. 中兴华会计师事务所（特殊普通合伙）营业执照复印件 2. 中兴华会计师事务所（特殊普通合伙）执业证书复印件 3. 注册会计师执业证书复印件 中兴华会计师事务所（特殊普通合伙） 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地 址 （ l o c a ...

一、计提减值准备的情况概述 证券代码：688246 证券简称：嘉和美康 公告编号：2025-033 嘉和美康（北京）科技股份有限公司 关于 2024 年年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）信用减值损失 公司以预期信用损失为基础，对应收票据、应收账款、其他应收款进行了减 值测试。经测试，本次需计提信用减值损失金额共计 5,418.77 万元。 嘉和美康（北京）科技股份有限公司（以下简称"公司"）根据《企业会计 准则第 8 号——资产减值》（以下简称"《企业会计准则》"）和相关会计政策的规 定，结合公司的实际情况，为客观、公允地反映公司截至 2024 年 12 月 31 日的 财务状况和 2024 年 1-12 月的经营成果，公司对截至 2024 年 12 月 31 日合并范 围内存在减值迹象的资产进行了减值测试并计提了相应的减值准备。公司 2024 年 1-12 月计提各类信用减值损失及资产减值损失共计人民币 11,874.16 万元， 具体情况如下： 单位：人民币万元 项目 2 ...

嘉和美康(北京)科技股份有限公司 关于 2024 年度"提质增效重回报行动方案"的年度 评估报告 嘉和美康(北京)科技股份有限公司（以下简称"公司"）为践行"以投资者 为本"的上市公司发展理念，维护公司全体股东利益，增强投资者信心，促进公 司长远健康可持续发展，基于对公司未来发展前景的信心和对公司价值的认可， 公司于 2024 年 7 月 17 日发布了 2024 年度"提质增效重回报"行动方案。 本公司始终坚守以投资者利益为核心的原则，通过不断深化主营业务，提升 公司业绩，稳固在行业中的领先地位，积极传递公司价值等多种方式提振投资者 信心。现将 2024 年度"提质增效重回报"行动方案的实施和效果评估情况报告 如下： 一、聚焦主业发展，持续优化产品品类，完善产品布局 2024 年，公司坚持以市场需求为导向，将医疗大数据、人工智能、云计算、 区块链以及 5G 等先进技术，全方位应用于医院的"医-教-研-管"全链条，打造 全场景智慧医院，引领医疗革新，重塑新质生产力，推动医院高质量发展。 1. 丰富智慧临床产品，临床业务和临床管理双维度同步推进 推出中枢化决策支持引擎及医疗 AI 应用开放平台，打造全院级智慧服 ...